IntelGenx Technologies Corp (IGXT)

[RobertJames]

IntelGenx (TSXV: IGX) (OTCQX: IGXT) to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015




Saint Laurent, Quebec--(Newsfile Corp. - March 23, 2015) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx", or the "Company") a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its 2014 annual results for the period and full year ended December 31, 2014, on March 31, 2015 at the open of the financial markets.

An accompanying conference call will be hosted by Dr. Horst Zerbe, President and Chief Executive Officer, and Paul Simmons, Chief Financial Officer, to discuss the results and provide a business update. The call will be held at 10:00 a.m. ET, on April 1, 2015. Please refer to the information below for conference call dial-in information and webcast registration.

Conference dial-in: 201-689-7817201-689-7817

International dial-in: 877-269-7756877-269-7756 FREE

Conference Call Name: IntelGenx Management Update Call

Webcast Registration: CLICK HERE (http://w.on24.com/r.htm?e=971685&s=1&k=9AC0B49C5995F1EF50418D4FD765A8F5)

Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.